Neurology Minute

Dr. Elizabeth Coon and Prof. Franziska Hopfner discuss the frequency and disease trajectory of MSA patients who do not experience dysautonomia, in comparison to those with autonomic involvement.

Show citation: 

Wilkens I, Bebermeier S, Heine J, et al. Multiple System Atrophy Without Dysautonomia: An Autopsy-Confirmed Study. Neurology. 2025;105(11):e214316. doi:10.1212/WNL.0000000000214316

Show transcript: 

Dr. Elizabeth Coon:

Welcome to the Neurology Minute. I'm Elizabeth Coon, and I'm delighted to welcome Professor Hopfner, who will give us a summary of her recently published paper in Neurology, "Multiple System Atrophy Without Dysautonomia and Aut...

In part one of this two-part series, Dr. Neishay Ayub discusses the history of a novel anti-epileptic drug, levetiracetam.

Show citations:

Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2008;4(3):507-523. doi:10.2147/ndt.s2937

Löscher W, Gillard M, Sands ZA, Kaminski RM, Klitgaard H. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond. CNS Drugs. 2016;30(11):1055-1077. doi:10.1007/s40263-016-0384-x

Rogawski MA. Brivaracetam: a rational drug discovery success story. Br J Pharmacol. 2008;154(8):1555-1557. doi:10.1038/bjp.2008.221

Ulloa CM, Towfigh A, Safdieh J. Review o...

Dr. Tesha Monteith discusses menstrual migraine and treatment options. 

In the January episode of the President's Spotlight, Dr. Jason Crowell and Dr. Natalia Rost discuss AAN's plans for 2026, including a general neurology boot camp, Autoimmune Conference, and new resources for members. 

Stay informed by watching the President's Spotlight video. 

Dr. Derek Stitt and Drs. Joseph Safdieh and Matthew S. Robbins discuss subspecialization's impact on patient care, why preserving a core neurologist identity matters, and how training can reinforce it.

Show citation:

Safdieh JE, Robbins MS. Opinion & Special Articles: The Core Identity of the Neurologist. Neurology. 2025;105(9):e214265. doi:10.1212/WNL.0000000000214265 

Dr. Shuvro Roy and Dr. Rosa Cortese discuss new ways to improve MS and MOGAD diagnosis, including how AI and imaging could enhance accuracy and influence future care.

Show citations: Cortese R, Sforazzini F, Gentile G, et al. Deep Learning Modeling to Differentiate Multiple Sclerosis From MOG Antibody-Associated Disease. Neurology. 2025;105(6):e214075. doi:10.1212/WNL.0000000000214075 

Dr. Bradley Ong discusses evidence for candesartan in migraine prevention.

Show citation:

Øie LR, Wergeland T, Salvesen Ø, et al. Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2025;24(10):817-827. doi:10.1016/S1474-4422(25)00269-8

In the second part of this two-part series, Dr. Shuvro Roy examines the study's findings and their implications for clinical practice moving forward.

Show citation:

Kim M, Park YH, Song YS, et al. Gait Improvement Following CSF Tap Test in NPH Patients With and Without Striatal Dopaminergic Deficit: A Preliminary Study. Neurol Clin Pract. 2025;15(6):e200549. doi:10.1212/CPJ.0000000000200549

In part one of this two-part series, Dr. Shuvro Roy explains idiopathic normal pressure hydrocephalus (iNPH), its diagnostic challenges, and a study on whether dopamine transporter (DAT) scan results affect gait improvement after a CSF tap test.

Show citation:

Kim M, Park YH, Song YS, et al. Gait Improvement Following CSF Tap Test in NPH Patients With and Without Striatal Dopaminergic Deficit: A Preliminary Study. Neurol Clin Pract. 2025;15(6):e200549. doi:10.1212/CPJ.0000000000200549

Drs. Mahinda Yogarajah, Benjamin Tolchin, and Jon Stone discuss recommendations for clinicians, patients, and other stakeholders on the management of functional seizures. 

Show citation:

Tolchin B, Goldstein LH, Reuber M, et al. Management of Functional Seizures Practice Guideline Executive Summary: Report of the AAN Guidelines Subcommittee. Neurology. 2026;106(1):e214466. doi:10.1212/WNL.0000000000214466 

Show transcript: 

Dr. Mahinda Yogarajah:

Welcome to this edition of Neurology Minute. I'm your host for this. My name's Mahinda Yogarajah. I've just finished interviewing Dr. Ben Tolchin and Jon Stone for this week's Neurology® Podcast. For today's Neurology Minu...

Drs. Greg Cooper, Natalia Rost, and Behnam Sabayan discuss preventive neurology and the need for neurologists to move beyond diagnosis and treatment toward proactive strategies for brain health. 

Show citation:

Sabayan B, Boden-Albala B, Rost NS. An Ounce of Prevention: The Growing Need for Preventive Neurologists. Neurology. 2025;105(1):e213785. doi:10.1212/WNL.0000000000213785

Show transcript: 

Dr. Greg Cooper:

Hi, this is Greg Cooper. I just finished interviewing Behnam Sabayan and Natalia Rost for this week's Neurology® Podcast. For today's Neurology Minute, I'm hoping you can tell us the main points of your...

In the final episode of this seven-part series, Dr. Jon Stone and Dr. Gabriela Gilmour wrap up the conversation discussing future directions.

Show citations:

Functional Neurological Disorder Society

Finkelstein SA, Carson A, Edwards MJ, et al. Setting up Functional Neurological Disorder Treatment Services: Questions and Answers. Neurol Clin. 2023;41(4):729-743. doi:10.1016/j.ncl.2023.04.002

Show transcript:

Dr. Gabriela Gilmour:

This is Gabriela Gilmour with the Neurology Minute. Jon Stone and I are back for our final episode of our seven-part series on functional neurological disorder. Today, we will discuss...

In part six of this seven-part series on FND, Dr. Jon Stone and Dr. Gabriela Gilmour discuss the prognosis of functional neurologic disorders. Show citation: Gelauff J, Stone J. Prognosis of functional neurologic disorders. Handb Clin Neurol. 2016;139:523-541. doi:10.1016/B978-0-12-801772-2.00043-6

Show transcript:

Dr. Jon Stone:

This is Jon Stone with the Neurology Minute. Gabriela Gilmour and I are back to continue with part six of our seven-part series on FND. Today we're going to talk about prognosis. What's the outlook for people with FND? It's obviously a question...

In part five of this seven-part series on FND, Dr. Jon Stone and Dr. Gabriela Gilmour discuss treatment options.

Show citation:

Gilmour, G.S., Nielsen, G., Teodoro, T. et al. Management of functional neurological disorder. J Neurol 267, 2164–2172 (2020). https://doi.org/10.1007/s00415-020-09772-w

Gilmour GS, Langer LK, Bhatt H, MacGillivray L, Lidstone SC. Factors Influencing Triage to Rehabilitation in Functional Movement Disorder. Mov Disord Clin Pract. 2024;11(5):515-525. doi:10.1002/mdc3.14007

Stone J, Carson A. Multidisciplinary Treatment for Functional Movement Disorder. Continuum (Minneap Minn). 2025;31(4):1182-1196. doi:10.1212/cont.0000000000001606

Tolchin B, Goldstein LH...

Dr. Zohaib Siddiqi talks with Dr. Catarina Bernardes about a case involving a 35-year-old woman presenting with personality changes and gait impairment. 

Show citation: 

Bernardes C, Lemos JM, Santo GC. Clinical Reasoning: A 35-Year-Old Woman With Personality Change and Gait Impairment. Neurology. 2025;104(2):e210252. doi:10.1212/WNL.0000000000210252 

Show transcript: 

Dr. Zohaib Siddiqi:

Hi, everyone. My name is Zohaib Siddiqi and I'm a fifth-year neurology resident and a part of the Neurology® Resident and Fellow Section Editorial Board.

I just finished interviewing Catarina Bernardes about her article, Clinical Reasoning: A 35-year...

In part four of this seven-part series on FND, Dr. Jon Stone and Dr. Gabriela Gilmour discuss the diagnostic explanation.

Show citation:

Gilmour GS, Lidstone SC. Moving Beyond Movement: Diagnosing Functional Movement Disorder. Semin Neurol. 2023;43(1):106-122. doi:10.1055/s-0043-1763505

Podcast transcript:

Dr. Gabriela Gilmour: This is Gabriela Gilmour with the Neurology Minute. Jon Stone and I are back to continue with part four, of seven, of our series on functional neurological disorder. Today we will...

In part three of this seven-part series on FND, Dr. Jon Stone and Dr. Gabriela Gilmour discuss causes of functional neurologic disorder.

Show citation:

Hallett M, Aybek S, Dworetzky BA, McWhirter L, Staab JP, Stone J. Functional neurological disorder: new subtypes and shared mechanisms. Lancet Neurol. 2022;21(6):537-550. doi:10.1016/S1474-4422(21)00422-1

Show transcript:

Dr. Gabriela Gilmour: This is Gabriela Gilmour with the Neurology Minute. Jon Stone and I are back to continue with part three of our seven-part series on functional neurological disorder. Today, we will focus on the causes of...

In part two of this two-part series on this year's World Stroke Congress, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss the ATLAS meta-analysis. 

Learn more on the World Stroke Congress website. 

In part two of this series, Dr. Jeff Ratliff and Dr. Dara Albert discuss what advice they have for people who care for patients with FND. 

Show citation: 

Miller R, Lidstone S, Perez DL, Albert DVF. Education Research: Targeting Self-Described Knowledge Gaps to Improve Functional Neurologic Disorder Education Among Clinicians. Neurol Educ. 2025;4(3):e200239. Published 2025 Sep 5. doi:10.1212/NE9.0000000000200239 

Drs. Dan Ackerman, Valérie Biousse, and Nancy J. Newman discuss the clinical presentations, diagnostic challenges, and the importance of accurate diagnosis in managing CRAO and BRAO. 

Show citation:

Bénard-Séguin É, Nahab F, Pendley AM, et al. Eye stroke protocol in in the emergency department. J Stroke Cerebrovasc Dis. 2024;33(9):107895. doi:10.1016/j.jstrokecerebrovasdis.2024.107895 

In part one of this two-part series on this year's World Stroke Congress, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss the TRIDENT trial. 

Learn more on the World Stroke Congress website. 

In part two of this seven-part series on FND, Dr. Jon Stone and Dr. Gabriela Gilmour discuss pitfalls in the diagnostic process. 

Show citation: 

Finkelstein SA, Popkirov S. Functional Neurological Disorder: Diagnostic Pitfalls and Differential Diagnostic Considerations. Neurol Clin. 2023;41(4):665-679. doi:10.1016/j.ncl.2023.04.001 

In part one of this seven-part series on FND, Dr. Jon Stone and Dr. Gabriela Gilmour discuss the process of diagnosing FND. 

Show citation: 

Aybek S, Perez DL. Diagnosis and management of functional neurological disorder. BMJ. 2022;376:o64. Published 2022 Jan 24. doi:10.1136/bmj.o64 

In the final episode of our five-part series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses bedside testing for PPA. 

Show citations: 

Show citations: 

Dr. Alex Menze and Dr. Kristen Dams-O'Connor discuss traumatic encephalopathy syndrome and its relationship with traumatic brain injury. 

Show Citation: 

Dams-O'Connor K, Selmanovic E, Pruyser A, et al. Traumatic Encephalopathy Syndrome in the Late Effects of Traumatic Brain Injury (LETBI) Study Cohort. Neurology. 2025;1(2):e000015.  doi:10.1212/WN9.0000000000000015

In part one of this series, Dr. Jeff Ratliff and Dr. Dara Albert discuss the themes or buckets that self-identified FND knowledge gaps fall into. 

Show citation: 

Miller R, Lidstone S, Perez DL, Albert DVF. Education Research: Targeting Self-Described Knowledge Gaps to Improve Functional Neurologic Disorder Education Among Clinicians. Neurol Educ. 2025;4(3):e200239. Published 2025 Sep 5. doi:10.1212/NE9.0000000000200239 

In the December episode of the President's Spotlight, Dr. Jason Crowell speaks with Dr. Natalia Rost to provide an overview of the Academy's journey through 2025. 

Show reference: 

https://www.aan.com/about-the-aan/presidents-spotlight  

In the final episode of our five-part series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses bedside testing for PPA. 

Show citations: 

In the fourth installment of our series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses semantic variant PPA. 

Show citations: 

In the third installment of our series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses nonfluent/agrammatic PPA. 

Show citations: 

Dr. Alex Menze and Professor Hakan Cetin discuss the need to reevaluate the approach to diagnosing and treating seronegative myasthenia gravis. 

Show citations: 

Krenn M, Wagner M, Schuller H, et al. Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing. Neurology. 2025;105(8):e214177. doi:10.1212/WNL.0000000000214177 

Dr. Gregg Day and Professor Jonathan Rohrer discuss the significance of studying individuals at risk of developing genetic frontotemporal dementia, focusing on how early cognitive changes before symptoms appear can inform research and future therapeutic trials. 

Show citation:

Russell LL, Bouzigues A, Convery RS, et al. Executive Function Deficits in Genetic Frontotemporal Dementia: Results From the GENFI Study. Neurol Genet. 2025;11(4):e200248. Published 2025 Jul 21. doi:10.1212/NXG.0000000000200248 

In the second installment of our series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses logopenic PPA. 

Show citations: 

In the first part of this series, Dr. Rogan Magee provides an introduction to primary progressive aphasia (PPA) and explains its three subtypes. 

Show citations: 

In this episode of the Neurology Minute, Dr. Nara Miriam Michaelson delves into another women's history minute to discuss Sylvia Lawry. 

Dr. Jason Crowell and Dr. YuHong Fu discuss the importance of differentiating between dementia with Lewy bodies and Parkinson disease dementia. 

Show citatiion: 

Fu Y, Halliday GM. Dementia with Lewy bodies and Parkinson disease dementia - the same or different and is it important?. Nat Rev Neurol. 2025;21(7):394-403. doi:10.1038/s41582-025-01090-x 

Dr. Dan Ackerman and Dr. Isabel Hostettler discuss the diagnosis, risk factors, and prognosis of RCVS, highlighting the need to recognize symptoms and distinguish it from other causes of subarachnoid hemorrhage. 

Show reference: 

Hostettler IC, Ponciano A, Wilson D, et al. Outcomes After Reversible Cerebral Vasoconstriction Syndrome With Convexity Subarachnoid Hemorrhage: Individual Patient Data Analysis. Neurology. 2025;105(5):e213984. doi:10.1212/WNL.0000000000213984 

In the November episode of the President's Spotlight, Dr. Jason Crowell talks with Dr. Natalia Rost about the Centers for Medicare & Medicaid Services final rule for how physicians are reimbursed in 2026. 

Show reference: 

https://www.aan.com/about-the-aan/presidents-spotlight  

Dr. Aaron Zelikovich discusses a recent article on nipocalimab and its role in treating generalized myasthenia gravis. 

Show citations: 

Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116. doi:10.1016/S1474-4422(24)00498-8

Dr. Katherine Havard Coiro discusses the 2024 McDonald Criteria for Multiple Sclerosis and how to interpret cerebrospinal fluid. 

Show reference: 

Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Montalban, Xavier, et al. The Lancet Neurology, Volume 24, Issue 10, 850 - 865 

In this episode of the Neurology Minute, Dr. Alison Christy delves into another women's history minute to discuss Marcelle Lapicque. 

Dr. Alison Christy and Dr. Matthew Ryan Woodward discuss the complexities of status epilepticus, focusing on its definitions, the transition to refractory and super-refractory states, and the implications for treatment. 

Show citation:

Woodward MR, Brown JP, Kittner SJ, et al. Super-Refractory Status Epilepticus Diagnosis, Management, and Prognostication: An International Survey Study. Neurol Clin Pract. 2025;15(5):e200520. doi:10.1212/CPJ.0000000000200520  

In the second part of this two-part series, Dr. Bradley Ong explains the four clinical phases of a typical migraine attack. 

Show citation: 

Lipton RB, Stokes J, Evans CJ, et al. Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing. Headache. 2025;65(8):1355-1368. doi:10.1111/head.15024 

In part one of this two-part series, Dr. Bradley Ong discusses the prodrome phase of migraine and how it represents the earliest stage of the attack. 

Show citation: 

Lipton RB, Stokes J, Evans CJ, et al. Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing. Headache. 2025;65(8):1355-1368. doi:10.1111/head.15024 

In part two of this series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss gender disparities in the treatment of multiple sclerosis. 

Show citation:

Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907 

In part one of this two-part series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss what disease-modifying therapies can be safely continued and strategically timed when pregnancy is anticipated. 

Show citation:

Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907 

Dr. Alison Christy and Dr. Jennifer L. McGuire discuss neuroimaging findings linked to ICANS, exploring whether specific imaging patterns correlate with distinct neurologic symptoms. 

Show citation: 

McGuire JL, Pinto S, Erdogan EN, et al. Neuroimaging Findings in Children and Young Adults With Neurotoxicity After CAR T-Cell Therapy for B-Cell Malignancies. Neurology. 2025;105(7):e214086. doi:10.1212/WNL.0000000000214086 

Dr. Alison Christy and Dr. Jennifer L. McGuire discuss neuroimaging findings linked to ICANS, exploring whether specific imaging patterns correlate with distinct neurologic symptoms. 

Show citation: 

McGuire JL, Pinto S, Erdogan EN, et al. Neuroimaging Findings in Children and Young Adults With Neurotoxicity After CAR T-Cell Therapy for B-Cell Malignancies. Neurology. 2025;105(7):e214086. doi:10.1212/WNL.0000000000214086 

In the final episode of this three-part series, Dr. Jeff Lambe addresses practical considerations surrounding the inclusion of the optic nerve as a topography for demonstrating dissemination in space. 

Show citation: 

Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24(10):850-865. doi:10.1016/S1474-4422(25)00270-4 

In part two of this three-part series, Dr. Jeff Lambe outlines how the optic nerve is being incorporated as one of five topographies used to demonstrate dissemination in space.

Show citation: 

Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24(10):850-865. doi:10.1016/S1474-4422(25)00270-4 

In part one of this three-part series, Dr. Jeff Lambe discusses the rationale for including the optic nerve in the 2024 revisions to the McDonald criteria. 

Show citation: 

Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24(10):850-865. doi:10.1016/S1474-4422(25)00270-4 

Dr. Katie Krulisky and Dr. Stefano Meletti discuss the incidence and characteristics of postictal central apnea in focal seizures.  

Show citation:

Meletti S, Burani M, Ballerini A, et al. Persistent Postictal Central Apnea in Focal Seizures: Incidence, Features, and Imaging Findings. Neurology. 2025;105(4):e213856. doi:10.1212/WNL.0000000000213856  

Dr. Greg Cooper and Dr. Claudia Suemoto discuss the association between consumption of low- and no-calorie sweeteners and cognitive decline. 

Show citations: 

Gonçalves NG, Martinez-Steele E, Lotufo PA, et al. Association Between Consumption of Low- and No-Calorie Artificial Sweeteners and Cognitive Decline: An 8-Year Prospective Study. Neurology. 2025;105(7):e214023. doi:10.1212/WNL.0000000000214023

Dr. Paul Crane discusses Oropouche virus and its neurologic complications. 

In the second part of this two-part series, Dr. Kaitlyn Palmer explains how these biomarkers change our approach to diagnosing multiple sclerosis. 

Show reference: 

Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Montalban, Xavier, et al. The Lancet Neurology, Volume 24, Issue 10, 850 - 865

In part one of this two-part series, Dr. Kaitlyn Palmer discusses two new MRI biomarkers to increase diagnostic specificity for multiple sclerosis. 

Show reference: 

Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Montalban, Xavier, et al. The Lancet Neurology, Volume 24, Issue 10, 850 - 865

Dr. Katie Krulisky and Dr. Rosemary Dray-Spira discuss the trends in prenatal exposure to antiseizure medications over the past decade. 

Show reference:

https://www.neurology.org/doi/10.1212/WNL.0000000000213933 

Citation: 

Pouneh S, Jérôme D, Sara M, et al. Trends in Prenatal Exposure to Antiseizure Medications Over the Past Decade: A Nationwide Study. Neurology. 2025;105(4): e213933. 

Dr. Greg Cooper and Dr. Jonathan Graff-Redford discuss the key takeaways from the recent Alzheimer's Association International Conference (AAIC). 

Dr. Margarita Fedorova discusses whether living near a golf course impacts the risk of Parkinson disease. 

Show reference: 

Krzyzanowski B, Mullan AF, Dorsey ER, et al. Proximity to Golf Courses and Risk of Parkinson Disease. JAMA Netw Open. 2025;8(5):e259198. doi:10.1001/jamanetworkopen.2025.9198 

In the second episode of this two-part series, Dr. Justin Abbatemarco and Dr. Jennifer E. Fugate discuss patient outcomes and how to manage these individuals both in the hospital and outside the hospital. 

Show reference:

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00232-7/abstract 

In the first episode of this two-part series, Dr. Justin Abbatemarco and Dr. Jennifer E. Fugate discuss posterior reversible encephalopathy syndrome (PRES), highlighting both typical and atypical MRI findings. 

Show reference:

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00232-7/abstract 

Dr. Gregg Day and Drs. Laura Baker and Melissa Yu discuss interventions that enhance or safeguard cognitive function in older adults at risk of cognitive decline and dementia. 

Show reference:

https://jamanetwork.com/journals/jama/article-abstract/2837046 

In the second part of this two-part series, Casey Kozak concludes the discussion about the TOAST criteria for classifying acute ischemic stroke. 

In the first part of this two-part series, Casey Kozak discusses the TOAST criteria for classifying acute ischemic stroke. In this episode, she covers large artery atherosclerosis and small vessel disease. 

In the final episode of this five-part series, Dr. Paul Crane concludes the measles series by discussing testing and prevention. 

In the fourth episode of this five-part series, Dr. Paul Crane discusses subacute sclerosing panencephalitis, a serious complication of measles. 

Dr. Jessica Ailani and Dr. Kathleen Digre discuss three key updates in the understanding and management of idiopathic intracranial hypertension. 

Show references:

https://jamanetwork.com/journals/jamaneurology/article-abstract/2836065

https://www.neurology.org/doi/10.1212/WNL.0000000000009312 

Dr. Andy Southerland and Dr. Amrou Sarraj examine whether general anesthesia (GA) compared with non-GA was associated with better functional outcomes in the SELECT2 trial. 

Show reference:

https://www.neurology.org/doi/10.1212/WNL.0000000000213819 

In the October episode of the President's Spotlight, Dr. Jason Crowell talks with Dr. Natalia Rost about the crucial role research plays in neurology for clinicians and scientists. 

Show reference: 

https://www.aan.com/about-the-aan/presidents-spotlight 

In this episode, Dr. Andy Southerland discusses the Capitol Hill Report from October 6th, covering the government shutdown and its potential impact on you and your patients. 

Stay updated with what’s happening on the hill by visiting aan.com/chr. 

Take a minute to email your members of Congress and ensure your voice is heard! 

In the second episode of this two-part series, Dr. Kiran Thakur and Dr. Ava Easton discuss how to get involved in advocacy efforts and policy development related to encephalitis. 

Show reference:

https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00057-6/fulltext 

In part one of this two-part series, Dr. Kiran Thakur and Dr. Ava Easton discuss the World Health Organization's technical brief on encephalitis. 

Show reference:

https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00057-6/fulltext  

In the third episode of this five-part series, Dr. Paul Crane discusses measles inclusion body encephalitis. 

In the third episode of this five-part series, Dr. Paul Crane discusses measles inclusion body encephalitis. 

In the second part of this five-part series, Dr. Paul Crane discusses the early neurologic complications associated with measles. 

In the first part of this five-part series, Dr. Paul Crane discusses the reemergence of measles and outlines steps to take if you suspect someone may have measles. 

In this episode, Dr. Andy Southerland discusses the Capitol Hill Report from September 8, providing important updates around BrainPAC.

Stay updated with what’s happening on the hill by visiting aan.com/chr. 

Learn how you can get involved with AAN advocacy. 

Dr. Deanna Saylor and Dr. Senjuti Saha discuss colonialism in global health and the importance of pathogen genomics. 

Show reference: 

https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00091-8/fulltext

In the final episode of this two-part series, Dr. Justin Abbatemarco discusses long-term maintenance therapy options. 

Show reference: 

https://www.neurology.org/doi/10.1212/CPJ.0000000000200504 

In part one of this two-part series, Dr. Justin Abbatemarco discusses what we know and don't know surrounding MOG antibody–associated diseases (MOGADs). 

Show reference: 

https://www.neurology.org/doi/10.1212/CPJ.0000000000200504 

In the final part of this three-part series, Dr. Justin Abbatemarco and Drs. John Chen and Smathorn Thakolwiboon discuss how to approach discontinuation of immunotherapy in clinical practice. 

Show reference: 

https://www.neurology.org/doi/10.1212/WNL.0000000000213903   

In part two of this three-part series, Dr. Justin Abbatemarco and Drs. John Chen and Smathorn Thakolwiboon discuss a long-term maintenance approach for MOGAD. 

Show reference: 

https://www.neurology.org/doi/10.1212/WNL.0000000000213903  

In part two of this two-part series, Dr. Robert Holloway and Dr. Carolyn Rennels discuss the future of addressing intolerable suffering in practice and explore the opportunities for MAID. 

Show reference:

https://www.neurology.org/doi/10.1212/CPJ.0000000000200478 

In part one of this two-part series, Dr. Robert Holloway and Dr. Carolyn Rennels discuss the main takeaway points from the paper. 

Show reference:

https://www.neurology.org/doi/10.1212/CPJ.0000000000200478

In part one of this three-part series, Dr. Justin Abbatemarco and Drs. John Chen and Smathorn Thakolwiboon discuss the outcomes following plasma exchange in MOGAD and explore how the findings from this study can inform patient care. 

Show reference: 

https://www.neurology.org/doi/10.1212/WNL.0000000000213903 

Dr. Justin Abbatemarco and Dr. Aaron Zelikovich discuss the safety and efficacy of satralizumab and its role in the current treatment landscape for myasthenia gravis. 

Show reference:

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00514-3/fulltext

Dr. Bradley Ong discusses the efficacy and safety of fremanezumab in adults with migraine and comorbid major depressive disorder.

Show reference:

https://jamanetwork.com/journals/jamaneurology/fullarticle/2833452 

In part two of this two-part series, Dr. Stacey Clardy and Dr. Walter Koroshetz discuss ways to empower professionals in the fields of neurology and research. 

In the first part of this two-part series, Dr. Stacey Clardy and Dr. Walter Koroshetz discuss strategies for advancing the fields of neurology and neuroscience research. 

Dr. Bakhtawar Ahmad discuss Ellen Grass the founder of the Grass Instruments Company, which played a vital role in the technological development of EEG in this women history minute. 

Dr. Paige Kalika discusses the importance of embracing neurodiversity in medicine. 

Show reference: 

https://jamanetwork.com/journals/jama/article-abstract/2830611 

Dr. Bradley Ong discusses a newly FDA-approved nasal powder formulation for treating debilitating migraine attacks.

In part two of this two-part series, Dr. Stacey Clardy and Dr. Andrew Mammen discuss what's new in the diagnosis and treatment of dermatomyositis. 

In the first part of this two-part series, Dr. Stacey Clardy and Dr. Andrew Mammen discuss the advancements made over the past decade regarding HMGCR antibody-associated myositis and how to treat it. 

In the September episode of the President's Spotlight, Dr. Jason Crowell and Dr. Natalia Rost highlight this year's AAN Brain Health Summit and discuss the events taking place. 

Show reference: 

https://www.aan.com/about-the-aan/presidents-spotlight 

https://www.aan.com/tools-resources/brain-health/brain-health-summit  

In the fourth episode of this series, Dr. Andy Southerland discusses the Capitol Hill Report from August 11th, where AAN members met with their local state representatives to discuss making telehealth flexibilities permanent and reforming prior authorization processes.

Stay updated with what’s happening on the hill by visiting aan.com/chr. 

Learn how you can get involved with AAN advocacy. 

In the final part of this series, Dr. Jeff Ratliff and Dr. Valtteri Kaasinen discuss how to speak with patients and families when having a conversation about an initial diagnosis of Parkinson disease.

Show reference:

https://www.neurology.org/doi/10.1212/WNL.0000000000213499  

Dr. Alex Menze and Dr. Christopher J. Klein discuss whether GLP-1RA usage is linked to radiculoplexus neuropathy and common fibular neuropathy. 

Show reference:

https://www.neurology.org/doi/10.1212/WNL.0000000000213916 

In part one of this series, Dr. Jeff Ratliff and Dr. Valtteri Kaasinen discuss what this study teaches us about the diagnosis of Parkinson disease once it is given to patients who are subsequently followed over time. 

Show reference:

https://www.neurology.org/doi/10.1212/WNL.0000000000213499 

In the final episode of this foundational neurology series, Casey Kozak discusses serotonin syndrome.